Dengue virus envelope dimer epitope monoclonal antibodies isolated from dengue patients are protective against zika virus

mBio

Volumn 7, Issue 4, 2016, Pages

  Swanstrom, J A ^a   Plante, J A ^a   Plante, K S ^b   Young, E F ^a,b   McGowan, E ^b   Gallichotte, E N ^a,b   Widman, D G ^a   Heise, M T ^b   de Silva, A M ^b   Baric, R S ^a,b  

^a University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; MONOCLONAL ANTIBODY; VIRUS ANTIBODY; NEUTRALIZING ANTIBODY;

AEDES ALBOPICTUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; INSECT CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; ZIKA FEVER; ZIKA VIRUS; ANIMAL; CROSS REACTION; DENGUE VIRUS; DISEASE MODEL; HUMAN; IMMUNOLOGY; SERODIAGNOSIS; TREATMENT OUTCOME; ZIKA VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CROSS REACTIONS; DENGUE VIRUS; DISEASE MODELS, ANIMAL; EPITOPES; HUMANS; MICE; NEUTRALIZATION TESTS; TREATMENT OUTCOME; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 84986564690     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01123-16     Document Type: Article

References (45)

1. Lazear HM, Diamond MS. 2016. Zika virus: new clinical syndromes and its emergence in the western hemisphere. J Virol 90:4864-4875. http://dx.doi.org/10.1128/JVI.00252-16.
2. Brasil P, Pereira JP, Jr, Raja Gabaglia C, Damasceno L, Wakimoto M, Ribeiro Nogueira RM, Carvalho de Sequeira P, Machado Siqueira A, Abreu de Carvalho LM, Cotrim da Cunha D, Calvet GA, Neves ES, Moreira ME, Rodrigues Baião AE, Nassar de Carvalho PR, Janzen C, Valderramos SG, Cherry JD, Bispo de Filippis AM, Nielsen-Saines K. 2016. Zika virus infection in pregnant women in Rio de Janeiro— preliminary report. N Engl J Med http://dx.doi.org/10.1056/NEJMoa1602412.
3. Brasil P, Calvet GA, Siqueira AM, Wakimoto M, de Sequeira PC, Nobre A, Quintana Mde S, Mendonca MC, Lupi O, de Souza RV, Romero C, Zogbi H, Bressan CDS, Alves SS, Lourenco-de-Oliveira R, Nogueira RM, Carvalho MS, de Filippis AM, Jaenisch T. 2016. Zika virus outbreak in Rio de Janeiro, Brazil: clinical characterization, epidemiological and virological aspects. PLoS Negl Trop 10:e0004636. http://dx.doi.org/10.1371/journal.pntd.0004636.
4. World Health Organization. 2016. Zika virus, microcephaly and Guillain-Barré syndrome. World Health Organization, Geneva, Switzerland.
5. Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN, Luz K. 2015. First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz 110:569-572. http://dx.doi.org/10.1590/0074-02760150192.
6. Cavalheiro S, Lopez A, Serra S, Da Cunha A, da Costa MD, Moron A, Lederman HM. 2016. Microcephaly and Zika virus: neonatal neuroradiological aspects. Childs Nerv Syst 32:1057-1060. http://dx.doi.org/10.1007/s00381-016-3074-6.
7. Mlakar J, Korva M, Tul N, Popovic´ M, Poljšak-Prijatelj M, Mraz J, Kolenc M, Resman Rus K, Vesnaver Vipotnik T, Fabjan Vodušek V, Vizjak A, Pižem J, Petrovec M, Avšič Županc T. 2016. Zika virus associated with microcephaly. N Engl J Med 374:951-958. http://dx.doi.org/10.1056/NEJMoa1600651.
8. Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR. 2016. Zika virus and birth defects—reviewing the evidence for causality. N Engl J Med 374:1981-1987. http://dx.doi.org/10.1056/NEJMsr1604338.
9. Araujo LM, Ferreira ML, Nascimento OJ. 2016. Guillain-Barre syndrome associated with the Zika virus outbreak in Brazil. Arq Neuropsiquiatr 74:253-255. http://dx.doi.org/10.1590/0004-282X20160035.
10. Brasil P, Sequeira PC, Freitas AD, Zogbi HE, Calvet GA, de Souza RV, Siqueira AM, de Mendonca MCL, Nogueira RMR, de Filippis AMB, Solomon T. 2016. Guillain-Barre syndrome associated with Zika virus infection. Lancet 387:1482. http://dx.doi.org/10.1016/S0140-6736(16)30058-7.
11. Beckham JD, Pastula DM, Massey A, Tyler KL. 2016. Zika virus as an emerging global pathogen: neurological complications of Zika virus. JAMA Neurol http://dx.doi.org/10.1001/jamaneurol.2016.0800.
12. Ye Q, Liu Z, Han J, Jiang T, Li X, Qin C. 2016. Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas. Infect Genet Evol 43:43-49. http://dx.doi.org/10.1016/j.meegid.2016.05.004.
13. Pitisuttithum P, Bouckenooghe A. 2016. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. Expert Rev Vaccines 15:795-798 http://dx.doi.org/10.1080/14760584.2016.1189331.
14. Sirivichayakul C, Barranco-Santana EA, Esquilin-Rivera I, Oh HM, Raanan M, Sariol CA, Shek LP, Simasathien S, Smith MK, Velez ID, Wallace D, Gordon GS, Stinchcomb DT. 2016. Safety and immunogenicity of a tetravalent dengue vaccine candidate in healthy children and adults in dengue-endemic regions: a randomized, placebo-controlled phase 2 study. J Infect Dis 213:1562-1572. http://dx.doi.org/10.1093/infdis/jiv762.
15. Vannice KS, Durbin A, Hombach J. 2016. Status of vaccine research and development of vaccines for dengue. Vaccine 34:2934-2938 http://dx.doi.org/10.1016/j.vaccine.2015.12.073.
16. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, Stanfield SM, Duffy MR. 2008. Genetic and serologic properties of Zika virus associated with an epidemic, Yap state, Micronesia, 2007. Emerg Infect Dis 14:1232-1239. http://dx.doi.org/10.3201/eid1408.080287.
17. Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Lok SM. 2014. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med 6:358-371. http://dx.doi.org/10.1002/emmm.201303404.
18. Fibriansah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim XN, Ooi JS, Kostyuchenko VA, Wang J, de Silva AM, Harris E, Crowe JE, Jr, Lok SM. 2015. Dengue virus. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science 349:88-91. http://dx.doi.org/10.1126/science.aaa8651.
19. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM. 2015. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun 6:6341. http://dx.doi.org/10.1038/ncomms7341.
20. Cockburn JJ, Navarro Sanchez ME, Goncalvez AP, Zaitseva E, Stura EA, Kikuti CM, Duquerroy S, Dussart P, Chernomordik LV, Lai CJ, Rey FA. 2012. Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J 31:767-779. http://dx.doi.org/10.1038/emboj.2011.439.
21. Henchal EA, Gentry MK, McCown JM, Brandt WE. 1982. Dengue virus-specific and flavivirus group determinants identified with monoclonal antibodies by indirect immunofluorescence. Am J Trop Med Hyg 31: 830-836.
22. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE. 2013. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. mBio 4:e00873-13. http://dx.doi.org/10.1128/mBio.00873-13.
23. Dejnirattisai W, Wongwiwat W, Supasa S, Zhang X, Dai X, Rouvinski A, Jumnainsong A, Edwards C, Quyen NTH, Duangchinda T, Grimes JM, Tsai W-Y, Lai C-Y, Wang W-K, Malasit P, Farrar J, Simmons CP, Zhou ZH, Rey FA, Mongkolsapaya J, Screaton GR. 2015. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol 16:170-177. http://dx.doi.org/10.1038/ni.3058.
24. Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, Duquerroy S, Vaney MC, Kikuti CM, Navarro Sanchez ME, Dejnirattisai W, Wongwiwat W, Haouz A, Girard-Blanc C, Petres S, Shepard WE, Desprès P, Arenzana-Seisdedos F, Dussart P, Mongkolsapaya J, Screaton GR, Rey FA. 2015. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520:109-113. http://dx.doi.org/10.1038/nature14130.
25. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.
26. Rossi SL, Tesh RB, Azar SR, Muruato AE, Hanley KA, Auguste AJ, Langsjoen RM, Paessler S, Vasilakis N, Weaver SC. 2016. Characterization of a novel murine model to study Zika virus. Am J Trop Med Hyg 94:1362-1369 http://dx.doi.org/10.4269/ajtmh.16-0111.
27. Lazear HM, Govero J, Smith AM, Platt DJ, Fernandez E, Miner JJ, Diamond MS. 2016. A mouse model of Zika virus pathogenesis. Cell Host Microbe 19:720-730. http://dx.doi.org/10.1016/j.chom.2016.03.010.
28. De Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 109:7439-7444. http://dx.doi.org/10.1073/pnas.1200566109.
29. Olkowski S, Forshey BM, Morrison AC, Rocha C, Vilcarromero S, Halsey ES, Kochel TJ, Scott TW, Stoddard ST. 2013. Reduced risk of disease during postsecondary dengue virus infections. J Infect Dis 208: 1026-1033. doi http://dx.doi.org/10.1093/infdis/jit273.
30. Wahala WM, Silva AM. 2011. The human antibody response to dengue virus infection. Viruses 3:2374-2395. http://dx.doi.org/10.3390/v3122374.
31. Dai L, Song J, Lu X, Deng YQ, Musyoki AM, Cheng H, Zhang Y, Yuan Y, Song H, Haywood J, Xiao H, Yan J, Shi Y, Qin CF, Qi J, Gao GF. 2016. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19:696-704. http://dx.doi.org/10.1016/j.chom.2016.04.013.
32. Kostyuchenko VA, Lim EX, Zhang S, Fibriansah G, Ng TS, Ooi JS, Shi J, Lok SM. 2016. Structure of the thermally stable Zika virus. Nature 533:425-428. http://dx.doi.org/10.1038/nature17994.
33. Lindesmith LC, Donaldson EF, Beltramello M, Pintus S, Corti D, Swanstrom J, Debbink K, Jones TA, Lanzavecchia A, Baric RS. 2014. Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope. J Virol 88:8826-8842. http://dx.doi.org/10.1128/JVI.01192-14.
34. Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE, Jr, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS. 2016. Functional transplant of a dengue virus serotype 3 (DENV3)-specific human monoclonal antibody epitope into DENV1. J Virol 90:5090-5097. http://dx.doi.org/10.1128/JVI.00155-16.
35. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, Jr, de Silva AM, Baric RS. 2015. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. mBio 6:e01461-15. http://dx.doi.org/10.1128/mBio.01461-15.
36. de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM. 2014. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog 10:e1004386 http://dx.doi.org/10.1371/journal.ppat.1004386.
37. Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS. 2008. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med 5:e31. http://dx.doi.org/10.1371/journal.pmed.0050031.
38. Young MK, Cripps AW, Nimmo GR, van Driel ML. 2015. Post-exposure passive immunisation for preventing rubella and congenital rubella syndrome. Cochrane Database Syst Rev 9:CD010586. http://dx.doi.org/10.1002/14651858.CD010586.pub2.
39. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T, Arossa A, Furione M, Rognoni V, Rizzo N, Gabrielli L, Klersy C, Gerna G, CHIP Study Group. 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:1316-1326. http://dx.doi.org/10.1056/NEJMoa1310214.
40. Nigro G, Adler SP, La Torre R, Best AM, Congenital Cytomegalovirus Collaborating Group. 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350-1362. http://dx.doi.org/10.1056/NEJMoa043337.
41. Nigro G, Adler SP, Parruti G, Anceschi MM, Coclite E, Pezone I, Di Renzo GC. 2012. Immunoglobulin therapy of fetal cytomegalovirus infection occurring in the first half of pregnancy—a case-control study of the outcome in children. J Infect Dis 205:215-227. http://dx.doi.org/10.1093/infdis/jir718.
42. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE, de Silva AM. 2012. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A 109:7439-7444. http://dx.doi.org/10.1073/pnas.1200566109.
43. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
44. Cai Z, Zhang T, Wan XF. 2010. A computational framework for influenza antigenic cartography. PLoS Comput Biol 6:e1000949. http://dx.doi.org/10.1371/journal.pcbi.1000949.
45. Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, Richardson C, Goodwin RR, Baehner F, Mendelman PM, Bargatze RF, Baric RS. 2015. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med 12:. http://dx.doi.org/10.1371/journal.pmed.1001807.